Creative Touch Permanent Makeup and Aesthetics

Irritant lip plumping agents are topically applied compounds that produce temporary lip fullness through a shared mechanism: activation of transient receptor potential (TRP) ion channels on cutaneous sensory nerve terminals, triggering the release of pro-inflammatory neuropeptides that cause local vasodilation and tissue oedema. The three agents most commonly encountered in cosmetic lip products – capsaicin, cinnamaldehyde (the primary active in cinnamon oil), and menthol – each act on a distinct TRP channel subtype, producing convergent inflammatory outcomes through divergent receptor pharmacology. The tingling, warming, or cooling sensation a user perceives is the direct nociceptive signal associated with that inflammatory event, not a secondary or incidental effect.

The plumping produced by these agents is real and measurable, but it is transient – resolving as neurogenic vasodilation subsides – and it is structurally unrelated to the hydration, collagen organisation, or tissue volume mechanisms that produce lasting lip appearance improvements. Repeated use does not build cumulative benefit; it builds cumulative barrier disruption. The lip’s structural vulnerability to this consequence is greater than facial skin in general: its stratum corneum equivalent is substantially thinner, its mucosal transition zone carries no sebaceous glands, and its baseline TEWL is higher – meaning that each cycle of neurogenic inflammation impairs a barrier that has limited capacity for self-repair.

Capsaicin

Capsaicin binds directly to TRPV1 (the vanilloid receptor), a Ca²⁺-permeable cation channel expressed on nociceptive C- and Aδ-fibre terminals, keratinocytes, and oral mucosal cells. Channel opening triggers depolarisation and antidromic release of substance P (SP) and calcitonin gene-related peptide (CGRP) from sensory nerve endings – neuropeptides that act on local vasculature to produce arteriolar dilation and plasma extravasation, generating the visible tissue swelling. ^[6] The lip carries higher TRPV1 receptor density than cheek mucosa, producing a more pronounced acute response at equivalent exposure concentrations. ^[1]

With repeated capsaicin exposure, TRPV1 undergoes tachyphylaxis: sustained channel activation triggers Ca²⁺-dependent receptor internalisation and degradation, progressively depleting surface TRPV1 availability. ^[9] The perceived tingling diminishes and the plumping effect weakens – but the underlying neurogenic inflammation continues through parallel signalling pathways even as receptor availability falls. ^[3] The practical consequence is a tolerance cycle in which habituation drives escalating use whilst barrier damage accrues without the sensory feedback that would ordinarily signal that damage is occurring. Notably, prior capsaicin desensitisation also partially attenuates the cinnamaldehyde-induced oedema response, indicating that the two agents share some downstream effector pathways despite acting on different receptors. ^[10]

Cinnamaldehyde

Cinnamaldehyde, the principal bioactive compound in cinnamon oil, is an electrophilic α,β-unsaturated aldehyde that activates TRPA1 (the ankyrin receptor) through covalent modification of cysteine residues on the channel’s intracellular domain – a distinct binding mechanism from the non-covalent agonism of capsaicin at TRPV1. ^[8] TRPA1 activation produces the same downstream neuropeptide release – SP via NK1 receptor-dependent mechanisms – and the same neurogenic vasodilation and oedema as TRPV1 activation, but through a separately regulated channel. ^[10] Cinnamaldehyde additionally induces cutaneous vasodilation through a nitric oxide synthase (NOS)-dependent endothelial mechanism, adding a vascular-direct component to the neurogenic response. ^[5]

The critical distinction from capsaicin is in the tolerance profile. Repeated topical application of cinnamaldehyde does not induce tachyphylaxis or desensitisation of the oedema response – the inflammatory reaction is reproduced at consistent magnitude with each application. ^[10] There is no progressive decline in perceived sensation that might reduce frequency of use, and no TRPA1-mediated equivalent of the TRPV1 internalisation mechanism that limits cumulative capsaicin exposure. For habitual users of cinnamon oil-containing plumpers, this makes cinnamaldehyde arguably the more problematic agent of the two: barrier disruption and leukocyte infiltration accumulate with each application at a rate that does not diminish, without the sensory tolerance signal that would otherwise prompt reduced use.

Menthol

Menthol acts primarily as an agonist of TRPM8 (the melastatin receptor), a non-selective cation channel activated by cool temperatures (8–28°C) and expressed on sensory nerve terminals, vascular endothelial cells, and vascular smooth muscle cells. ^[2] TRPM8 activation by menthol triggers cutaneous vasodilation through multiple parallel mechanisms: endothelial Ca²⁺ influx driving nitric oxide (NO) and endothelium-derived hyperpolarising factor (EDHF) release, smooth muscle RhoA/ROCK pathway suppression, and sensory nerve-mediated vasodilatory signalling. ^[11] At higher concentrations, menthol additionally activates TRPA1 directly, producing a neurogenic inflammatory component overlapping with cinnamaldehyde’s mechanism. ^[7]

The perceived sensation – cooling rather than warming – creates a different user experience from capsaicin and cinnamaldehyde, and menthol occupies a different cultural position: it appears not only in plumping products but in mainstream lip balms marketed for freshness and soothing properties, often in formulations intended for dry or sensitive lips. This context makes its barrier consequences less intuitive to the consumer. The same TRPM8-mediated vasodilation and downstream inflammatory signalling that produces the plumping effect also increases TEWL and compromises barrier integrity with repeated use – an outcome that is directly counterproductive in a product used to address lip dryness. TRPM8 is now understood to play a role in maintaining skin barrier integrity, and its repeated pharmacological stimulation through menthol appears to disrupt rather than support that function. ^[4]

Shared Receptor Pharmacology

All three produce the same macroscopic outcome – transient vasodilation, tissue swelling, barrier disruption – through receptor-level pharmacology that is distinct enough that cross-tolerance between agents is limited. A habitual user who tolerates capsaicin will not have desensitised to cinnamaldehyde or menthol, and combining agents in a single formulation does not produce equivalent tachyphylaxis to single-agent exposure.